14,900 Shares in NewAmsterdam Pharma Company N.V. $NAMS Purchased by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. acquired a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 14,900 shares of the company’s stock, valued at approximately $522,000.

A number of other hedge funds have also modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after buying an additional 437 shares in the last quarter. Swedbank AB bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $3,189,000. Lisanti Capital Growth LLC grew its holdings in shares of NewAmsterdam Pharma by 278.1% during the fourth quarter. Lisanti Capital Growth LLC now owns 179,410 shares of the company’s stock worth $6,294,000 after buying an additional 131,965 shares in the last quarter. Legato Capital Management LLC grew its holdings in shares of NewAmsterdam Pharma by 258.7% during the fourth quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock worth $2,941,000 after buying an additional 60,463 shares in the last quarter. Finally, Mizuho Markets Cayman LP bought a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $1,680,000. 89.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Guggenheim boosted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.00.

NewAmsterdam Pharma Trading Down 4.9%

Shares of NASDAQ NAMS opened at $33.68 on Friday. NewAmsterdam Pharma Company N.V. has a 12 month low of $16.95 and a 12 month high of $42.21. The stock has a 50 day moving average of $33.34 and a 200-day moving average of $34.20. The company has a market capitalization of $3.94 billion, a P/E ratio of -18.82 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million for the quarter. Analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the completion of the sale, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,850.60. This trade represents a 60.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. The trade was a 71.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 881,512 shares of company stock valued at $28,350,236. 12.74% of the stock is owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.